Fig. 1From: Evaluation of recombinant human erythropoietin responsiveness by measuring erythrocyte creatine content in haemodialysis patientsStudy protocol. Erythropoiesis stimulating agent (ESA) treatment was fixed 3 months prior to the enrollment and was maintained during 6 months period. Laboratory tests were performed at baseline and haemoglobin was measured 3 months laterBack to article page